Biogen (NASDAQ:BIIB) Issues Earnings Results

Biogen (NASDAQ:BIIB) issued its quarterly earnings results on Wednesday. The biotechnology company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63, FiscalAI reports. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. During the same period in the previous year, the business posted $4.81 earnings per share. The business’s revenue was up 10.6% compared to the same quarter last year.

Here are the key takeaways from Biogen’s conference call:

• Q3 revenue grew 11% year over year to $2.8 billion, driven by the growth portfolio and the first full quarter of SYFOVRE and EMPAVELI following the Apellis acquisition. Biogen raised the low end of its 2026 non-GAAP EPS outlook to $12.20–$13.00.
• The Apellis integration is progressing faster than expected, with the transaction now roughly operating-income neutral and at least $250 million in run-rate synergies targeted by the end of 2027. Biogen also expects the deal to be accretive to non-GAAP EPS in 2027.
• Biogen reported strong momentum across key growth products, including high-dose SPINRAZA, LEQEMBI, SKYCLARYS, SYFOVRE and EMPAVELI. The company said its growth portfolio represented approximately 63% of core pharmaceutical revenue and expects to return to overall top-line growth in 2026.
• The company highlighted a series of potentially important clinical catalysts, beginning with phase III SLE data for litifilimab in December and followed by readouts in cutaneous lupus, AMR and Dravet syndrome. Biogen also reported five INDs in 2026 and plans to build an early-stage pipeline of at least 20 programs over the next several years.
• Several reported Q3 sales benefited from temporary factors, including SPINRAZA conversion doses and inventory builds for SKYCLARYS and SYFOVRE, which are expected to reverse in Q4; contract manufacturing revenue is also expected to decline. VUMERITY revenue fell 11% year over year due to tighter Part D formulary management, while the upcoming pipeline readouts remain subject to clinical and regulatory risk.

Biogen Price Performance

NASDAQ BIIB traded down $2.13 during mid-day trading on Wednesday, reaching $250.59. The stock had a trading volume of 537,599 shares, compared to its average volume of 1,206,587. Biogen has a 1 year low of $138.00 and a 1 year high of $258.78. The company has a fifty day moving average price of $225.10 and a 200 day moving average price of $200.10.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted earnings of $2.62 per share, exceeding the Zacks consensus estimate of $2.06 and the broader consensus cited by MarketBeat of $1.99. Revenue reached $2.804 billion, above expectations of roughly $2.63 billion and up 11% year over year. Biogen Inc. Tops Q3 Earnings and Revenue Estimates
• Positive Sentiment: Growth Portfolio revenue rose 49% to $1.26 billion, benefiting from the first full quarter of contributions from acquired Apellis products. Total product revenue increased 13%, while rare-disease revenue grew 27% to $676 million, supporting the diversification strategy beyond multiple sclerosis treatments. Biogen Q3 Revenue Rises 11% as GAAP Loss Widens
• Positive Sentiment: Management raised the lower end of its 2026 reported non-GAAP diluted EPS outlook, now guiding to $12.20–$13.00. Piper Sandler also maintained its Buy rating, reinforcing bullish sentiment around Biogen’s growth products and acquisitions. Piper Sandler Maintains Buy Rating
• Neutral Sentiment: Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, versus year-ago GAAP earnings of $466.5 million, primarily reflecting $284 million of acquired in-process research and development, upfront and milestone expenses tied largely to the RayThera acquisition. These are significant near-term charges but may support future growth.
• Negative Sentiment: GAAP earnings declined sharply from $3.17 to a loss of $0.14 per share, and the stock’s strong recent run has raised concerns that much of the expected improvement is already reflected in its valuation. Biogen also ended the quarter with approximately $7.7 billion of debt, a consideration as acquisition spending continues.

Analyst Upgrades and Downgrades

BIIB has been the subject of a number of research analyst reports. Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and lifted their price target for the company from $190.00 to $235.00 in a research report on Monday, July 13th. HC Wainwright lifted their target price on shares of Biogen from $237.00 to $251.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. raised shares of Biogen from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $210.00 to $300.00 in a research note on Monday, October 12th. Wedbush increased their price target on shares of Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, July 30th. Finally, Wells Fargo & Company raised their price objective on shares of Biogen from $250.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $241.89.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.